You are here

CLL

Eagle Pharmaceuticals Receives New Patent for Bendeka Configure

Eagle Pharmaceuticals Receives New Patent for Bendeka Configure

CP Wire

Eagle Pharmaceuticals

Teva Pharmaceuticals

Flag link:

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

Endpoints

chronic lymphocytic leukemia

Flag link:

AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks

AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks

Fierce Pharma

Flag link:

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

Xconomy

Infinity Pharma

follicular lymphoma

small lymphocytic lymphoma

Flag link:

Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

Fierce Pharma

chronic lymphocytic leukemia

Flag link:

#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL

#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL

Endpoints

chronic lymphocytic leukemia

Flag link:

FDA says yes to rapid-acting Rituxan

FDA says yes to rapid-acting Rituxan

BioPharma Dive

refractory follicular lymphoma

diffuse large B-cell lymphoma

Flag link:

TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK

TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK

Endpoints

TG Therapeutics

Flag link:

AbbVie’s Imbruvica Expected to Become a Leading Oncology Drug

AbbVie’s Imbruvica Expected to Become a Leading Oncology Drug

Market Realist

Flag link:

JNJ's Expensive Leukemia Drug Wins British Nod

JNJ's Expensive Leukemia Drug Wins British Nod

Investopedia

chronic lymphocytic leukemia

Flag link:

Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee

Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee

Yahoo/GuruFocus

chronic lymphocytic leukemia

Flag link:

AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Yahoo

small lymphocytic lymphoma

Flag link:

Updated survival data added to Imbruvica's label

Updated survival data added to Imbruvica's label

BioPharma Dive

Flag link:

AbbVie wins FDA approval for leukemia drug

AbbVie wins FDA approval for leukemia drug

BioPharma Dive

Flag link:

J&J, AbbVie's Imbruvica breaks into larger CLL market with first-line FDA nod

J&J, AbbVie's Imbruvica breaks into larger CLL market with first-line FDA nod

Fierce Pharma

chronic lymphocytic leukemia

Flag link:

Will This Study Finally Catapult Gilead Sciences Into a Cancer Powerhouse?

Will This Study Finally Catapult Gilead Sciences Into a Cancer Powerhouse?

Motley Fool

Gilead Sciences

chronic lymphocytic leukemia

Flag link:

Can new PhIII data help Gilead's Zydelig stage a comeback in CLL?

Can new PhIII data help Gilead's Zydelig stage a comeback in CLL?

Fierce Pharma Marketing

Gilead Sciences

chronic lymphocytic leukemia

Flag link:

U.K. cost gatekeeper gives thumbs-up to Gilead's Zydelig for CLL

U.K. cost gatekeeper gives thumbs-up to Gilead's Zydelig for CLL

Fierce Pharma

Gilead Sciences

chronic lymphocytic leukemia

Flag link:

AbbVie edges closer to Imbruvica deal payoff with another FDA filing

AbbVie edges closer to Imbruvica deal payoff with another FDA filing

Fierce Pharma

chronic lymphocytic leukemia

Flag link:

Novartis team tracks remissions of 4-plus years in a pioneering CAR-T study

Novartis team tracks remissions of 4-plus years in a pioneering CAR-T study

Fierce Biotech

chronic lymphocytic leukemia

Flag link:

Pages